Photocatalytic intermolecular bromonitroalkylation of styrenes: synthesis of cyclopropylamine derivatives and their evaluation as LSD1 inhibitors

被引:2
|
作者
Kim, Darong [1 ]
Jeon, Hui-Jeon [1 ]
Kwak, Yoonna [1 ]
Lee, Sun Joo [1 ]
Nam, Tae-Gyu [2 ]
Yu, Ji Hoon [1 ]
An, Hongchan [3 ]
Hong, Ki Bum [1 ]
机构
[1] Daegu Gyeongbuk Med Innovat Fdn DGMIF, New Drug Dev Ctr NDDC, 80 Cheombok Ro, Daegu 41061, South Korea
[2] Hanyang Univ ERICA, Inst Pharmaceut Sci & Technol, Coll Pharm, Dept Pharm, Ansan 15588, Gyeonggi, South Korea
[3] CHA Univ, Inst Pharmaceut Sci, Coll Pharm, 120 Haeryong Ro, Pochon 11160, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Bromine compounds - Cyclization - Styrene;
D O I
10.1039/d3ra07830b
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A mild and efficient method for photoredox-catalyzed bromonitroalkylation of alkenes is described herein. In this reaction, bromonitromethane serves as a source of both nitroalkyl and bromine for direct and regioselective formation of C-Br and C-C bonds from alkenes, and additional cyclization provides C-C bonds to the cyclopropylamine core as an LSD1 inhibitor. A mild and efficient method for photoredox-catalyzed bromonitroalkylation of alkenes is described herein.
引用
收藏
页码:831 / 835
页数:5
相关论文
共 50 条
  • [41] Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment
    Ma, Qi-Sheng
    Zhang, Yi-Fan
    Li, Cheng-Yang
    Zhang, Wei-Xin
    Yuan, Lu
    Niu, Jin-Bo
    Song, Jian
    Zhang, Sai-Yang
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 251
  • [42] Development and evaluation of selective, reversible LSD1 inhibitors from fragment startpoints.
    Stowell, Alex
    Hamilton, Niall
    Hitchin, James
    Blagg, Julian
    Burke, Rosemary
    Burns, Samantha
    Cockerill, Mark J.
    Fairweather, Emma
    Hutton, Colin
    Jordan, Allan
    Mould, Daniel
    Thomson, Graeme
    Waddell, Ian
    Ogilvie, Donald
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [43] Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375
    Yan, Jiangkun
    Gu, Yanting
    Sun, Yixiang
    Zhang, Ziheng
    Zhang, Xiangyu
    Wang, Xinran
    Wu, Tianxiao
    Zhao, Dongmei
    Cheng, Maosheng
    ARCHIV DER PHARMAZIE, 2021, 354 (08)
  • [44] Synthesis and biological evaluation of coumarin-1,2,3-triazole-dithiocarbamate hybrids as potent LSD1 inhibitors
    Ye, Xian-Wei
    Zheng, Yi-Chao
    Duan, Ying-Chao
    Wang, Meng-Meng
    Yu, Bin
    Ren, Jing-Li
    Ma, Jin-Lian
    Zhang, En
    Liu, Hong-Min
    MEDCHEMCOMM, 2014, 5 (05) : 650 - 654
  • [45] Medicinal chemistry insights in the discovery of novel LSD1 inhibitors
    Wang, Xueshun
    Huang, Boshi
    Suzuki, Takayoshi
    Liu, Xinyong
    Zhan, Peng
    EPIGENOMICS, 2015, 7 (08) : 1379 - 1396
  • [46] Annual review of LSD1/KDM1A inhibitors in 2020
    Fu, Dong-Jun
    Li, Jun
    Yu, Bin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 214
  • [47] Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia
    Przespolewski, Amanda
    Wang, Eunice S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (07) : 771 - 780
  • [48] What potential is there for LSD1 inhibitors to reach approval for AML?
    Pandey, Manu R.
    Wang, Eunice S.
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (04) : 205 - 212
  • [49] LSD1 inhibitors: a patent review (2010-2015)
    Stazi, Giulia
    Zwergel, Clemens
    Valente, Sergio
    Mai, Antonello
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (05) : 565 - 580
  • [50] Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing
    Li, Zhonghua
    Qin, Tingting
    Li, Zhongrui
    Zhao, Xuan
    Zhang, Xinhui
    Zhao, Taoqian
    Yang, Nian
    Miao, Jinxin
    Ma, Jinlian
    Zhang, Zhenqiang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 225